People
Megan McMellon
Senior Associate
London
Senior Associate
Biography
Megan helps clients navigate global transactions involving IP development and exploitation, as well as complex supply chains and other commercial arrangements.
Megan is Co- Lead Associate for the Consumer & Retail sector and has a particular focus on the Life Sciences and Consumer & Retail sectors. Megan advises on strategic collaboration and licensing transactions, as well as the IP/commercial aspects of M&A transactions. Her broad experience covers all stages of the product life cycle, including early-stage research, technology transfer, manufacturing and supply, distribution, sponsorship and other commercialisation activities. Megan is valued by her clients for her genuine interest in their strategic aims and her understanding of the commercial practicalities behind the transactions she advises on. She has a global perspective, having worked in the firm's London, New York and Hong Kong offices. Megan has been ranked by Legal500 as a leading associate for life sciences and healthcare since 2024, and by IP STARS as a rising star since 2025. She also received the IP Rising Star award at the LMG Life Sciences Awards in 2025.
Practice areas
- Artificial intelligence
- Complex commercial transactions
- Intellectual property
- M and A JVs and corporate reorganizations
- Tech transactions
- Corporate and M&A
Sectors
- Consumer and retail
- Life sciences and healthcare
Selected experience
- GSK on: Its development and licensing agreement with SiranBio for oligonucleotide drug candidate SA030 targeting metabolic and vascular risk across lung, liver and kidney disease. Its development and licensing agreement with Frontier Biotechnologies for two small interfering RNA pipeline products targeting kidney disease. The IP/IT aspects of its acquisition of RAPT Therapeutics. Its AI license and partnership with AI-native biotech Noetik, under which Noetik will license two cancer research foundation models to GSK. Its COVID/flu mRNA vaccine settlement and licensing arrangements with BioNTech, CureVac and Pfizer. Its research collaboration with the University of Oxford establishing the GSK-Oxford Cancer Immuno-Prevention Programme. Its licensing arrangements with CureVac for influenza/COVID mRNA vaccines.
- Its development and licensing agreement with SiranBio for oligonucleotide drug candidate SA030 targeting metabolic and vascular risk across lung, liver and kidney disease.
- Its development and licensing agreement with Frontier Biotechnologies for two small interfering RNA pipeline products targeting kidney disease.
- The IP/IT aspects of its acquisition of RAPT Therapeutics.
- Its AI license and partnership with AI-native biotech Noetik, under which Noetik will license two cancer research foundation models to GSK.
- Its COVID/flu mRNA vaccine settlement and licensing arrangements with BioNTech, CureVac and Pfizer.
- Its research collaboration with the University of Oxford establishing the GSK-Oxford Cancer Immuno-Prevention Programme.
- Its licensing arrangements with CureVac for influenza/COVID mRNA vaccines.
- Shionogi on: Its hearing loss collaboration with, and investment into, Salubritas. Its hearing loss collaboration with, and investment into, Cilcare. Its joint venture with Apnimed for the development of therapies for obstructive sleep apnea and other sleep disorders, and subsequent acquisition of Apnimed’s equity interest. Its licence agreement with the Medicines Patent Pool for Shionogi’s COVID-19 antiviral candidate ensitrelvir fumaric acid to allow qualified generic manufacturers to manufacture and supply ensitrelvir in up to 117 low- and middle-income countries. Its strategic collaboration with F2G to develop and commercialize a new antifungal agent for invasive fungal infections in Europe and Asia.
- Its hearing loss collaboration with, and investment into, Salubritas.
Education
- BA (Hons) Law and Business Studies (Qualifying Degree), First Class, University of Warwick, 2016
- Postgraduate Diploma in Legal Practice, Distinction, BPP University, 2017
- Certificate in IP Transactions: Law and Practice, Distinction, University College London, 2020
- European Pharma Law Academy, 2022
Admissions
- Admitted as a Solicitor (England and Wales), 2019